Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 4/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | CFD | P00746 | 1/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | CTSG | P08311 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4313901 | 0.85 | ALOX5 (0.50) | ALOX5ELANEF2PTPN1CTSG | |
| SCHEMBL3347282 | 0.83 | ALOX5 (0.45) | ALOX5ELANEF2CTSGHSP90AA1 | |
| SCHEMBL27512435 | 0.82 | MTNR1B (0.57) | MAPTMAPK1ALDH1A1 | |
| SCHEMBL531084 | 0.82 | PTGS2 (0.54) | PTPN1CYP3A4MAPTMAPK1ALDH1A1 | |
| SCHEMBL6706457 | 0.81 | KDM4E (0.52) | ALOX5ELANEF2CTSGMAPT | |
| SCHEMBL5801725 | 0.81 | ALOX5 (0.56) | ALOX5ELANEF2CTSG | |
| SCHEMBL4848267 | 0.80 | CYP3A4 (0.50) | ALOX5PTPN1CFDAKT1CYP3A4 | |
| SCHEMBL343656 | 0.80 | ALOX5 (0.59) | ALOX5ELANEF2 | |
| SCHEMBL9164207 | 0.80 | AKT1 (0.55) | ELANECFDAKT1 | |
| SCHEMBL11110381 | 0.79 | RECQL (0.53) | MAPTALDH1A1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140004071-A1 | Thermochromic Dental Material | BROWN WILLIAM STEVEN (US) | 2014-01-02 | — | — | US | disclosed |
| US-7638648-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7468391-B2 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | ALLERGAN, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| CN-100360325-C | Multicolor thermal recording medium | JUJO PAPER CO LTD (JP) | 2008-01-09 | — | — | CN | disclosed |
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-7226951-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1699775-A2 | COMPOUNDS HAVING SELECTIVE CYTOCHROME P450RAI-1 OR SELECTIVE CYTOCHROME P450RAI-2 INHIBITORY ACTIVITY AND METHODS OF OBTAINING THE SAME | Allergan, Inc. (US) | 2006-09-13 | — | — | EP | disclosed |
| EP-1696899-A1 | METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B | ALLERGAN, INC. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050187298-A1 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | ALLERGAN, INC. (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050176689-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. | 2005-08-11 | — | — | US | disclosed |
| CN-1638973-A | multicolor thermosensitive recording medium | JUJO PAPER CO LTD (JP) | 2005-07-13 | — | — | CN | disclosed |
| WO-2005058798-A2 | COMPOUNDS HAVING SELECTIVE CYTOCHROME P450RAI-1 OR SELECTIVE CYTOCHROME P450RAI-2 INHIBITORY ACTIVITY AND METHODS OF OBTAINING THE SAME | ALLERGAN, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005058301-A1 | METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B | ALLERGAN, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| US-6432874-B1 | POSTAGE STAMPS | NIPPON PAPER INDUSTRIES CO, LTD (JP) | 2002-08-13 | — | — | US | disclosed |
| US-6184300-B1 | USEFUL AS HEAT-INSULATING MATERIAL, ORGANIC PIGMENT, OR OPACIFYING AGENT, AND AS HEAT-INSULATING INTERLAYER TO BE FORMED IN THERMAL RECORDING MATERIAL | NIPPON ZEON CO., LTD. (JP) | 2001-02-06 | — | — | US | disclosed |
| EP-0366461-B1 | Optical recording medium | JUJO PAPER CO LTD (JP) | 1997-02-19 | — | — | EP | disclosed |
| US-5075146-A | Containing heat sensitive color developable layer on infrared absorbent substrates | JUJO PAPER CO., LTD. (JP) | 1991-12-24 | — | — | US | disclosed |
| EP-0366461-A2 | Optical recording medium | NIPPON PAPER INDUSTRIES CO., LTD. (JP) | 1990-05-02 | — | — | EP | disclosed |
| US-4853362-A | Heat-sensitive recording sheet | JUJO PAPER CO., LTD. (JP) | 1989-08-01 | — | — | US | disclosed |
| US-4590499-A | MONOBENZYL CALCIUM PHTHALATE OR ZINC P-NITROBENZOATE AS STABILIZER IN THE CHROMOGEN LAYER; OIL REPELLENTS | JUJO PAPER CO., LTD. (JP) | 1986-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176689-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | CYP1A2, CYP2A7, CYP3A7 | ALOX5 624/4885ELANE 3594/4885F2 1272/4885 |
| US-20050187298-A1 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | CYP26B1, CYP2A6, CYP21A2 | ALOX5 653/4885ELANE 2719/4885F2 3756/4885 |
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | CYP1A2, CYP2A7, CYP3A7 | ALOX5 624/4885ELANE 3594/4885F2 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.